Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call. All participants will be able to listen only until the question-and-answer portion of this call. We do not expect any technical difficulties today; however, in the event […]
Enrollment Initiated in Second Phase III Clinical Study for Ivonescimab, HARMONi-3
Continuing Enrollment of HARMONi Phase III Study, with Enrollment Completion Expected in Second Half of.
Mr. Soni Invests $5 Million in Summit while Joining Executive Team
In Corresponding Appointments, Dave Gancarz, Urte Gayko, PhD, Fong Clow, DSc, & Allen S. Yang, MD, PhD, Elevated to Newly.